How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy?

@article{Castra2011HowTA,
  title={How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy?},
  author={Laurent Cast{\'e}ra and Pierre Bedossa},
  journal={Liver international : official journal of the International Association for the Study of the Liver},
  year={2011},
  volume={31 Suppl 1},
  pages={13-7}
}
The assessment of liver fibrosis is a major issue in the management of patients with chronic hepatitis C. Liver biopsy has traditionally been considered the gold standard for the evaluation of tissue damage, including fibrosis. In addition, it detects associated lesions such as steatosis, steatohepatitis or iron overload, which provide useful information for patient management and prognosis. Liver biopsy is, however, an invasive procedure, with a risk of rare but potentially life-threatening… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

Role of liver biopsy in the era of direct-acting antivirals.

Current gastroenterology reports • 2013
View 5 Excerpts
Highly Influenced

Non-invasive prediction of Liver fibrosis and cirrhosis

Simona Kasputyt, Monika Petraityt, Arnas Karu, As
2017
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 54 references

15–20

Intraobserver, interobserver variations in liver biopsy interpretation in patie 1994, 20
Liver International • 2011
View 2 Excerpts

257–64

Michalak S Dupre F et al. Sources of variability in histolo Rousselet MC, 41
Liver International • 2011
View 1 Excerpt

Antifibrotic therapies—emerging biomarkers as treatment end points

Nature Reviews Gastroenterology &Hepatology • 2010
View 1 Excerpt

Similar Papers

Loading similar papers…